Table 5.
Risk of death from all causes, by HLA–DRB1 and PTPN22 genotypes, in subgroups of patients with and without RF or anti-CCP at baseline*
| RF status at baseline (n = 946) |
Anti-CCP status at baseline (n = 858) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Negative |
Positive |
Negative |
Positive |
|||||
| HLA–DRB1 and PTPN22 groups | No. of patients | HR (95% CI) | No. of patients | HR (95% CI) | No. of patients | HR (95% CI) | No. of patients | HR (95% CI) |
| 0 copies of SE alleles (comparator) | 305 | 1.00 | 81 | 1.90 (1.23–2.93) | 261 | 1.00 | 40 | 1.35 (0.74–2.46) |
| 1 copy of SE alleles | 293 | 0.97 (0.67–1.39) | 133 | 1.42 (0.95–2.10) | 229 | 0.78 (0.53–1.16) | 108 | 1.03 (0.66–1.61) |
| 2 copies of SE alleles | 73 | 1.41 (0.81–2.46) | 61 | 1.94 (1.17–3.24) | 46 | 0.86 (0.39–1.91) | 56 | 1.57 (0.896–2.77) |
| 0 or 1 SE allele (comparator) | 598 | 1.00 | 214 | 1.61 (1.21–2.15) | 490 | 1.00 | 148 | 1.26 (0.89–1.80) |
| 2 SE alleles | 73 | 1.43 (0.85–2.42) | 61 | 1.97 (1.23–3.17) | 46 | 0.99 (0.46–2.13) | 56 | 1.79 (1.05–3.04) |
| 0 or 1 SE allele (comparator) | 598 | 1.00 | 214 | 1.61 (1.21–2.15) | 490 | 1.00 | 148 | 1.26 (0.89–1.80) |
| HLA–DRB1*01/*01 | 10 | 1.99 (0.49–8.09) | 2 | † | 8 | 1.20 (0.17–8.67) | 0 | – |
| HLA–DRB1*01/*04 | 33 | 1.90 (0.99–3.63) | 23 | 3.07 (1.49–6.31) | 23 | 1.05 (0.42–2.59) | 18 | 2.73 (1.18–6.29) |
| HLA–DRB1*0101/*0401 | 20 | 1.79 (0.87–3.7) | 13 | 2.13 (0.79–5.79) | 13 | 0.99 (0.36–2.72) | 11 | 2.60 (0.95–7.10) |
| HLA–DRB1*0101/*0404 | 7 | 2.44 (0.34–17.63) | 5 | 4.15 (1.01–17.04) | 5 | 2.89 (0.40–21.08) | 4 | 2.17 (0.30–15.72) |
| HLA–DRB1*04/*04 | 25 | 0.77 (0.24–2.42) | 34 | 1.65 (0.89–3.07) | 13 | 1.12 (0.15–8.06) | 37 | 1.44 (0.72–2.86) |
| HLA–DRB1*0401/*0401 | 7 | 1.00 (0.14–7.22) | 7 | 3.08 (1.13–8.42) | 5 | 1.59 (0.22–11.53) | 7 | 2.82 (0.69–11.54) |
| HLA–DRB1*0401/*0404 | 9 | 0.45 (0.06–3.23) | 22 | 1.57 (0.73–3.37) | 4 | † | 22 | 1.42 (0.62–3.25) |
| PTPN22*1858T allele | ||||||||
| Negative (comparator) | 418 | 1.00 | 138 | 1.50 (1.02–2.21) | 369 | 1.00 | 121 | 1.54 (1.0–2.37) |
| Positive | 120 | 1.34 (0.85–2.12) | 49 | 1.14 (0.60–2.16) | 106 | 1.25 (0.77–2.05) | 46 | 1.23 (0.63–2.39) |
*
Data were adjusted for age at symptom onset and sex. RF = rheumatoid factor; anti-CCP = anti–cyclic citrullinated peptide; HR = hazard ratio; 95% CI = 95% confidence interval; SE = shared epitope.
†
Too few deaths to provide robust hazard ratio estimates.